Biodesix, Inc.

BDSX | $1.225 1.24% 1.22% 45K

(0.0% 1d) (-7.4% 1m) (-29.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (12.25% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 118,754,025
http://www.biodesix.com
Sec Filling | Patents | n/a employees

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.

cancer lung cancer genomic t-cell lungs diagnostics ceiling

add to watch list Paper trade email alert is off